Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Arcturus Therapeutics Holdings (ARCT) over the last 5 years, with Q3 2025 value amounting to $27.2 million.

  • Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) rose 46.56% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 46.56%. This contributed to the annual value of $27.0 million for FY2024, which is 139.7% up from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Shares Outstanding (Diluted Average) stood at $27.2 million for Q3 2025, which was up 46.56% from $27.1 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) registered a high of $27.2 million during Q3 2025, and its lowest value of $26376.0 during Q1 2022.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $26.8 million (2023), whereas its average is $22.4 million.
  • In the last 5 years, Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) crashed by 9989.96% in 2022 and then surged by 10283069.46% in 2023.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Shares Outstanding (Diluted Average) stood at $26.3 million in 2021, then rose by 2.95% to $27.1 million in 2022, then decreased by 1.72% to $26.6 million in 2023, then increased by 1.4% to $27.0 million in 2024, then increased by 0.7% to $27.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $27.2 million for Q3 2025, versus $27.1 million for Q2 2025 and $27.1 million for Q1 2025.